Volume 65, Issue 1, Pages (January 2014)

Slides:

Advertisements

Similar presentations

Volume 60, Issue 6, Pages (December 2011)

Advertisements

Judith Bosschieter, André N. Vis, Henk G. van der Poel, Luc M

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 44, Issue 6, Pages (December 2003)

Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive.

Testosterone Therapy in Men With Prostate Cancer

Volume 66, Issue 6, Pages (December 2014)

Volume 57, Issue 6, Pages (June 2010)

Volume 60, Issue 6, Pages (December 2011)

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 51, Issue 1, Pages (January 2007)

Volume 53, Issue 5, Pages (May 2008)

Volume 70, Issue 6, Pages (December 2016)

Volume 51, Issue 3, Pages (March 2007)

Volume 70, Issue 2, Pages (August 2016)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 72, Issue 5, Pages (November 2017)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 56, Issue 3, Pages (September 2009)

Volume 63, Issue 1, Pages (January 2013)

Nomograms for Bladder Cancer

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 5, Pages (November 2007)

Volume 53, Issue 4, Pages (April 2008)

Volume 191, Issue 1, Pages (January 2014)

Volume 67, Issue 3, Pages (March 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 57, Issue 4, Pages (April 2010)

NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima,

Volume 68, Issue 1, Pages (July 2015)

Volume 61, Issue 5, Pages (May 2012)

Prostate Cancer Epidemic in Sight?

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 2, Pages (August 2014)

Volume 67, Issue 6, Pages (June 2015)

Volume 62, Issue 2, Pages (August 2012)

European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update

Volume 47, Issue 1, Pages (January 2005)

Volume 53, Issue 1, Pages (January 2008)

Volume 70, Issue 2, Pages (August 2016)

Volume 50, Issue 5, Pages (November 2006)

Elliot L. Chaikof, MD, PhD, Robert B. Smith, MD, Atef A

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

Volume 54, Issue 6, Pages (December 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Bladder Cancer: Highlights from 2006

European Urology is “Your” Journal

Volume 54, Issue 2, Pages (August 2008)

Volume 53, Issue 6, Pages (June 2008)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Disease-Free Interval Length Correlates to Prognosis of Patients Who Underwent Metastasectomy for Esophageal Lung Metastases Satoshi Shiono, MD, Masafumi.

Presentation transcript:

Volume 65, Issue 1, Pages 227-234 (January 2014) The Predictive Value of C-reactive Protein for Prognosis in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Multi-institutional Study Nobuyuki Tanaka, Eiji Kikuchi, Suguru Shirotake, Kent Kanao, Kazuhiro Matsumoto, Hiroaki Kobayashi, Yasumasa Miyazaki, Hiroki Ide, Jun Obata, Katsura Hoshino, Nozomi Hayakawa, Yujiro Ito, Takeo Kosaka, Kiichiro Kodaira, Masafumi Oyama, Akira Miyajima, Tetsuo Momma, Ken Nakagawa, Munehisa Ueno, Mototsugu Oya European Urology Volume 65, Issue 1, Pages 227-234 (January 2014) DOI: 10.1016/j.eururo.2012.11.050 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Recurrence-free survival rate after radical nephroureterectomy for a serum C-reactive protein level ≤0.50mg/dl and between 0.51 and 2.00mg/dl versus >2.00mg/dl preoperatively. Pre-CRP=preoperative C-reactive protein. European Urology 2014 65, 227-234DOI: (10.1016/j.eururo.2012.11.050) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Cancer-specific survival rate after radical nephroureterectomy for a serum C-reactive protein level ≤0.50mg/dl or between 0.51 and 2.00mg/dl versus >2.00mg/dl preoperatively. Pre-CRP=preoperative C-reactive protein. European Urology 2014 65, 227-234DOI: (10.1016/j.eururo.2012.11.050) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Cancer-specific survival rate after radical nephroureterectomy for a postoperative serum C-reactive protein (CRP) level ≤0.50mg/dl versus >0.50mg/dl in subgroup analysis using 96 patients with elevated preoperative CRP levels. Post-CRP=postoperative C-reactive protein. European Urology 2014 65, 227-234DOI: (10.1016/j.eururo.2012.11.050) Copyright © 2012 European Association of Urology Terms and Conditions